Dose-Response: An International Journal: Volume 9, Issue 2
No Thumbnail Available
Volume
Number
Issue Date
2011-30-06
Journal Title
Journal ISSN
Journal Volume
Articles
PRACTICAL RISK ASSESSMENT AND MANAGEMENT ISSUES ARISING WERE WE TO ADOPT LOW-DOSE LINEARITY FOR ALL ENDPOINTS
(2011-06-01) Rhomberg, Lorenz R
The 2009 National Research Council report, Science and Decisions, proposes harmonizing dose-response approaches for cancer and non-cancer endpoints, and for non-cancer quantitative risk assessment, this would usually take the form of a low-dose linear nothreshold dose-response curve. The soundness of this recommendation has been questioned, but I focus on its consequences if adopted, many of them apparently unintended. If most endpoints for most agents are assumed to have non-zero low-dose risks, then the critical –effect concept, choosing the one endpoint on which to calculate acceptable doses, loses its basis. All regulatory decisions, since they entail substituting some exposures (and their attendant risks) for others, become risk-risk trade-off decisions, and equity questions are raised since risk transfer is inevitably involved. A valid basis for estimating low-dose linear components is not evident, and upper-bound approaches fail to be reliably public health-protective owing to the risk trade-off decisions that need to be faced.
HORMESIS IN REGULATORY RISK ASSESSMENT - SCIENCE AND SCIENCE POLICY
(2011-06-01) Gray, George
This brief commentary will argue that whether hormesis is considered in regulatory risk assessment is a matter less of science than of science policy. I will first discuss the distinction between science and science policy and their roles in regulatory risk assessment. Then I will focus on factors that influence science policy, especially as it relates to the conduct of risk assessments to inform regulatory decisions, with a focus on the U.S. Environmental Protection Agency (EPA). The key questions will then be how does hormesis interact with current concepts of science and science policy for risk assessment? Finally, I look ahead to factors that may increase, or decrease, the likelihood of hormesis being incorporated into regulatory risk assessment.
METHAMPHETAMINE PRECONDITIONING CAUSES DIFFERENTIAL CHANGES IN STRIATAL TRANSCRIPTIONAL RESPONSES TO LARGE DOSES OF THE DRUG
(2011-06-01) Cadet, Jean Lud; Brannock, Christie; Ladenheim, Bruce; McCoy, Michael T; Beauvais, Genevieve; Hodges, Amber B.; Lehrmann, Elin; Wood III, William H; Becker, Kevin G; Krasnova, Irina N
Methamphetamine (METH) is a toxic drug of abuse, which can cause significant decreases in the levels of monoamines in various brain regions. However, animals treated with progressively increasing doses of METH over several weeks are protected against the toxic effects of the drug. In the present study, we tested the possibility that this pattern of METH injections might be associated with transcriptional changes in the rat striatum, an area of the brain which is known to be very sensitive to METH toxicity and which is protected by METH preconditioning. We found that the presence and absence of preconditioning followed by injection of large doses of METH caused differential expression in different sets of striatal genes. Quantitative PCR confirmed METH-induced changes in some genes of interest. These include small heat shock 27 kD proteins 1 and 2 (HspB1 and HspB2), brain derived neurotrophic factor (BDNF), and heme oxygenase-1 (Hmox-1). Our observations are consistent with previous studies which have reported that ischemic or pharmacological preconditioning can cause reprogramming of gene expression after lethal ischemic insults. These studies add to the growing literature on the effects of preconditioning on the brain transcriptome.
GENERIC HOCKEY-STICK MODEL FOR ESTIMATING BENCHMARK DOSE AND POTENCY: PERFORMANCE RELATIVE TO BMDS AND APPLICATION TO ANTHRAQUINONE
(2011-06-01) Bogen, Kenneth T
Benchmark Dose Model software (BMDS), developed by the U.S. Environmental Protection Agency, involves a growing suite of models and decision rules now widely applied to assess noncancer and cancer risk, yet its statistical performance has never been examined systematically. As typically applied, BMDS also ignores the possibility of reduced risk at low doses (“hormesis”). A simpler, proposed Generic Hockey-Stick (GHS) model also estimates benchmark dose and potency, and additionally characterizes and tests objectively for hormetic trend. Using 100 simulated dichotomous-data sets (5 dose groups, 50 animals/group), sampled from each of seven risk functions, GHS estimators performed about as well or better than BMDS estimators, and a surprising observation was that BMDS mis-specified all of six non-hormetic sampled risk functions most or all of the time. When applied to data on rodent tumors induced by the genotoxic chemical carcinogen anthraquinone (AQ), the GHS model yielded significantly negative estimates of net potency exhibited by the combined rodent data, suggesting that—consistent with the anti-leukemogenic properties of AQ and structurally similar quinones—environmental AQ exposures do not likely increase net cancer risk. In addition to its simplicity and flexibility, the GHS approach offers a unified, consistent approach to quantifying environmental chemical risk.
POSTCONDITIONING HORMESIS PUT IN PERSPECTIVE: AN OVERVIEW OF EXPERIMENTAL AND CLINICAL STUDIES
(2011-06-01) Wiegant, FAC; Prins, HAB; Van Wijk, R
A beneficial effect of applying mild stress to cells or organisms, that were initially exposed to a high dose of stress, has been referred to as ‘postconditioning hormesis’. The initial high dose of stress activates intrinsic self-recovery mechanisms. Modulation of these endogenous adaptation strategies by administration of a subsequent low dose of stress can confer effects that are beneficial to the biological system. Owing to its potentially therapeutic applications, postconditioning hormesis is subject to research in various scientific disciplines. This paper presents an overview of the dynamics of postconditioning hormesis and illustrates this phenomenon with a number of examples in experimental and clinical research.